{
      "Rank": 357,
      "Acronym": [
            "PD"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Autologous Hope Biosciences adipose derived mesenchymal stem cells.",
            "Sterile Saline Solution 0.9%"
      ],
      "ArmGroupInterventionName": [
            "Biological: HB-adMSCs",
            "Other: Placebo",
            "Biological: HB-adMSCs",
            "Other: Placebo"
      ],
      "ArmGroupLabel": [
            "HB-adMSCs",
            "Placebo"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04928287"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple HB-adMSCs vs Placebo for the treatment of Parkinson's disease.\n\nThe trial includes a screening period of up to 4 weeks, a 32-week treatment period, and a safety Follow-up period of 20 weeks after the last investigational product administration.\n\nThis clinical trial will be open to enroll 24 eligible participants diagnosed with Parkinson's disease. Patients' recruitment will be conducted by the study team, if eligible participants are identified based on eligibility criteria, a screening visit will be scheduled. Informed consent form will be given to the study participants and signed before any study procedures. Informed consent form will include information about the clinical trial and some aspects should be considered during this process."
      ],
      "BriefTitle": [
            "Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "INDUSTRY"
      ],
      "CollaboratorName": [
            "Hope Biosciences"
      ],
      "CompletionDate": [
            "May 28, 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Parkinson Disease"
      ],
      "ConditionAncestorId": [
            "D000020734",
            "D000001480",
            "D000001927",
            "D000002493",
            "D000009422",
            "D000009069",
            "D000080874",
            "D000019636"
      ],
      "ConditionAncestorTerm": [
            "Parkinsonian Disorders",
            "Basal Ganglia Diseases",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Movement Disorders",
            "Synucleinopathies",
            "Neurodegenerative Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC10",
            "All",
            "BC04",
            "BC17",
            "BC18"
      ],
      "ConditionBrowseBranchName": [
            "Nervous System Diseases",
            "All Conditions",
            "Neoplasms",
            "Skin and Connective Tissue Diseases",
            "Nutritional and Metabolic Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Parkinson's Disease"
      ],
      "ConditionBrowseLeafId": [
            "M12365",
            "M21647",
            "M24756",
            "M3926",
            "M15510",
            "M4356",
            "M4894",
            "M11181",
            "M2217",
            "M20711"
      ],
      "ConditionBrowseLeafName": [
            "Parkinson Disease",
            "Parkinsonian Disorders",
            "Ganglion Cysts",
            "Basal Ganglia Diseases",
            "Synovial Cyst",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Movement Disorders",
            "Synucleinopathies",
            "Neurodegenerative Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000010300"
      ],
      "ConditionMeshTerm": [
            "Parkinson Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [
            "A parallel study is a type of clinical study where two groups of treatments, A (HB-adMSCs) and B (Placebo), are given so that one group receives only A while another group receives only B."
      ],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [
            "Study subjects, investigators and study staff will be blinded to the assigned treatment."
      ],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nA study participant will be eligible for inclusion in this study only if all of the following criteria apply:\n\nMale and female participants 18 - 75 years of age.\nStudy participant must have been diagnosed with early and/or moderate Parkinson's disease at least 6 months before study participation.\nStudy participants must have previously banked their mesenchymal stem cells with Hope Biosciences.\nStudy participants should be able to read, understand and to provide written consent.\nVoluntarily signed informed consent obtained before any clinical-trial related procedures are performed.\nFemale study participants should not be pregnant or plan to become pregnant during study participation and for 6 months after last investigational product administration.\nMale participants if their sexual partners can become pregnant should use a method of contraception during study participation and for 6 months after the last administration of the investigated product.\nStudy participant is able and willing to comply with the requirements of this clinical trial.\n\nExclusion Criteria:\n\nA study participant will not be eligible for inclusion in this clinical trial if any of the following criteria apply:\n\nPregnancy, lactation. Women of childbearing age who are not pregnant but do not take effective contraceptive measures.\nStudy participants with advanced Parkinson's disease described as, severe disability, wheelchair bound or bedridden.\nStudy participant has any active malignancy, including evidence of cutaneous basal, squamous cell carcinoma or melanoma.\nStudy participant has known alcoholic addiction or dependency or has current substance use or abuse.\n\nStudy participant has 1 or more significant concurrent medical conditions (verified by medical records), including the following:\n\nPoorly controlled diabetes mellitus (PCDM) defined as history of deficient standard of care treatment and/or pre-prandial glucose >130mg/dl during screening visit or post-prandial glucose >200mg/dl.\nMedical History of Chronic kidney disease (CKD) diagnosis and/or screening results of eGFR < 59mL/min/1.73m2.\nPresence of New York Heart Association (NYHA) Class III/IV heart failure during screening visit.\nAny medical history of myocardial infarction in any of the different types, such as ST-elevation myocardial infarction (STEMI) or non-ST-elevated myocardial infarction (NSTEMI), coronary spasm, or unstable angina.\nMedical history of uncontrolled high blood pressure defined as a deficient standard of care treatment and/or blood pressure > 180/120 mm/Hg during screening visit.\nMedical history of inherited thrombophilias, recent major general surgery, (within 12 months before the Screening), lower extremity paralysis due to spinal cord injury, fracture of the pelvis, hips or femur, cancer of the lung, brain, lymphatic, gynecologic system (ovary or uterus), or gastrointestinal tract (like pancreas or stomach).\nHistory of brain surgery for Parkinson's disease.\nStudy participant has received any stem cell treatment within 6 months before first dose of investigational product other than stem cells produced by Hope Biosciences.\nReceiving any investigational therapy or any approved therapy for investigational use within 1 year prior first dose of the investigational product other than COVID-19 vaccines.\n\nStudy participant has a laboratory abnormality during screening, including the following:\n\nWhite blood cell count < 3000/mm3\nPlatelet count < 80,000mm3\nAbsolute neutrophil count < 1500/mm3\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) 10 upper limit of normal (ULN) x 1.5\nStudy participant has any other laboratory abnormality or medical condition which, in the opinion of the investigator, poses a safety risk or will prevent the subject from completing the study.\nStudy participant is unlikely to complete the study or adhere to the study procedures.\nStudy participant with known concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection.\nStudy participant has a previously diagnosed psychiatric condition which in the opinion of the investigator may affect self-assessments.\nStudy participant with any systemic infection requiring treatment with antibiotics, antivirals, or antifungals within 30 days prior to first dose of the investigational product.\nMale study participants who plan to donate sperm during the study or within 6 months after the last dose. Female patients who plan to donate eggs or undergo in vitro fertilization treatment during the study or within 6 months after the last dose.\nStudy participants who are determined by the Investigator to be unsuitable for study enrollment for other reasons"
      ],
      "EnrollmentCount": [
            "24"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "HB-adMSCs",
            "Placebo",
            "HB-adMSCs",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M21013"
      ],
      "InterventionBrowseLeafName": [
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "HB-adMSCs will be administered intravenously to study participants who qualify.",
            "Placebo will be administered intravenously to study participants who qualify."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "HB-adMSCs",
            "Placebo"
      ],
      "InterventionOtherName": [
            "Autologous Hope Biosciences adipose derived mesenchymal stem cells.",
            "Sterile Saline Solution 0.9%"
      ],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "July 21, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "July 20, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Hope Biosciences Stem Cell Research Foundation"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Sugar Land"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "Hope Biosciences Stem Cell Research Foundation"
      ],
      "LocationState": [
            "Texas"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "77478"
      ],
      "MaximumAge": [
            "75 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "\"A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease\""
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Hope Biosciences"
      ],
      "OrgStudyId": [
            "HBPD03"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hope Biosciences Stem Cell Research Foundation"
      ],
      "OverallOfficialName": [
            "Djamchid Lotfi, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Active, not recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "May 28, 2023"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "MDS-UPDRS Part II.",
            "treatment-emergent Adverse Event.",
            "SSAEs.",
            "Incidence of thromboembolic events.",
            "Incidence and risk of AEs of special interest (serious or non-serious), including peripheral events defined as, thromboembolism of the extremities.",
            "Incidence and risk of AEs of special interest (serious or non-serious), including infections.",
            "Incidence and risk of AEs of special interest (serious or non-serious), including hypersensitivities.",
            "Clinically significant changes in CBC values.",
            "Clinically significant changes in CMP values.",
            "Clinically significant changes in Coagulation Panel values.",
            "Clinically significant changes in Respiratory Rate.",
            "Clinically significant changes in Heart Rate.",
            "Clinically significant changes in Heart Rate.",
            "Clinically significant changes in Blood Pressure.",
            "Clinically significant changes in Weight in lb.",
            "Clinically significant changes in general physical examination results.",
            "Clinically significant changes in body systems physical examination results."
      ],
      "PrimaryOutcomeMeasure": [
            "Changes in MDS-UPDRS Part II.",
            "Incidence of treatment-emergent Adverse Event (TEAEs).",
            "Incidence of treatment-emergent Serious Adverse Events (SAEs).",
            "AEs of special interest (serious or non-serious) - thromboembolic events.",
            "AEs of special interest (serious or non-serious) - thromboembolism of the extremities",
            "AEs of special interest (serious or non-serious) - infections",
            "AEs of special interest (serious or non-serious) - hypersensitivities.",
            "Laboratory values. CBC",
            "Laboratory values. CMP",
            "Laboratory values. Coagulation Panel",
            "Vital signs. - Respiratory Rate (breaths per minute)",
            "Vital signs. - Heart Rate (beats per minute)",
            "Vital signs. - Body Temperature (Fahrenheit )",
            "Vital signs. - Blood Pressure (mmHg)",
            "Weight in lb.",
            "Physical examination results. General",
            "Physical examination results. Body Systems."
      ],
      "PrimaryOutcomeTimeFrame": [
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52.",
            "Baseline to Weeks 52."
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "MDS-UPDS Parts I, II, III and IV.",
            "Non-Motor Aspects of Experiences of Daily Living (nM-EDL), including complex behaviors such as, cognitive impairment, hallucinations and psychosis, depressed mood, anxious mood, apathy, features of dopamine dysregulation syndrome, sleep problems, daytime sleepiness, pain and other sensations, urinary problems, constipation problems, light headedness on standing and fatigue.",
            "Motor Examination, including speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination movements of hands, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, global spontaneity of movement (body bradykinesia), postural tremor of the hands, kinetic tremor of the hands, rest tremor amplitude, constancy of rest tremor, dyskinesias impact and Hoehn and Yahr stage.",
            "Motor Complications, including time spent with dyskinesias and others.",
            "Communication - Short Form",
            "Ability to Participate in Social Roles and Activities - Short Form",
            "Anxiety - Short Form",
            "Depression - Short Form",
            "Emotional and Behavioral Dyscontrol - Short Form",
            "Fatigue - Short Form",
            "Lower Extremity Function (Mobility) - Short Form",
            "Positive Affect and Well-Being - Short Form",
            "Sleep Disturbance - Short Form",
            "Upper Extremity Function (Fine Motor, ADL) - Short Form",
            "Stigma-Short Form",
            "Satisfaction with Social Roles and Activities - Short Form",
            "Cognition Function- Short Form",
            "Score of \u22658 indicates the presence of significant fatigue.",
            "Difficulties across the 8 quality of life dimensions of functioning of wellbeing.",
            "Visual Analog Scale for Pain.",
            "Dosage of medications.",
            "Adverse Event (TEAEs)",
            "Including thromboembolic events, peripheral events defined as, thromboembolism of the extremities, also infections and hypersensitivities.",
            "CBC",
            "Visual Analog Scale for muscle spasms.",
            "Changes in Respiratory Rate.",
            "Changes in Heart Rate.",
            "Changes in Body Temperature.",
            "Changes in Blood Pressure.",
            "Changes in Oxygen Saturation.",
            "Physical examination results.",
            "Weight in lb.",
            "CMP",
            "Coagulation Panel"
      ],
      "SecondaryOutcomeMeasure": [
            "Changes in MDS-UPDS total score.",
            "Changes in MDS-UPDRS Part I.",
            "Changes in MDS-UPDRS Part III.",
            "Changes in MDS-UPDRS Part IV.",
            "Changes in Neuro-QOL. - Communication",
            "Changes in Neuro-QOL. - Social Roles and Activities",
            "Changes in Neuro-QOL. - Anxiety",
            "Changes in Neuro-QOL. - Depression",
            "Changes in Neuro-QOL. - Dyscontrol",
            "Changes in Neuro-QOL. - Fatigue",
            "Changes in Neuro-QOL. - Mobility",
            "Changes in Neuro-QOL. - Well-Being",
            "Changes in Neuro-QOL. - Sleep",
            "Changes in Neuro-QOL. - Fine Motor",
            "Changes in Neuro-QOL. - Stigma",
            "Changes in Neuro-QOL. - Social Roles",
            "Changes in Neuro-QOL. - Cognition",
            "Changes in Parkinson's disease fatigue scale (PFS-16).",
            "Changes in Parkinson's disease Questionnaire (PDQ-39).",
            "Changes in Visual Analog Scale for Pain.",
            "Changes in Dosage of medications taken to treat Parkinson's disease.",
            "Incidence of treatment-emergent Adverse Event (TEAEs) and serious Adverse Events (SAEs).",
            "Incidence and risk of AEs of special interest (serious or non-serious),",
            "Clinically significant changes in laboratory values. - CBC",
            "Changes in Visual Analog Scale for muscle spasms.",
            "Clinically significant changes in vital signs. - Respiratory Rate",
            "Clinically significant changes in vital signs. - Heart Rate",
            "Clinically significant changes in vital signs. - Body Temperature.",
            "Clinically significant changes in vital signs. - Blood Pressure.",
            "Clinically significant changes in vital signs. - Oxygen Saturation.",
            "Clinically significant changes in physical examination results.",
            "Clinically significant changes in weight in lb.",
            "Clinically significant changes in laboratory values. - CMP",
            "Clinically significant changes in laboratory values. - Coagulation Panel"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
            "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52."
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "June 28, 2021"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "July 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 16, 2021"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "May 26, 2021"
      ],
      "StudyFirstSubmitQCDate": [
            "June 14, 2021"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}